Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review

被引:56
|
作者
Dimitrakopoulou-Strauss, Antonia [1 ]
Ronellenfitsch, Ulrich [2 ]
Cheng, Caixia [1 ]
Pan, Leyun [1 ]
Sachpekidis, Christos [1 ]
Hohenberger, Peter [2 ]
Henzler, Thomas [3 ]
机构
[1] German Canc Res Ctr, Clin Cooperat Unit Nucl Med, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Div Surg Oncol & Thorac Surg,Dept Surg, Mannheim, Germany
[3] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Inst Clin Radiol & Nucl Med, Mannheim, Germany
关键词
Molecular imaging; PET; GIST; Oncology; Therapy monitoring; Personalized medicine; POSITRON-EMISSION-TOMOGRAPHY; DUAL-ENERGY CT; IMATINIB MESYLATE TREATMENT; SOFT-TISSUE SARCOMA; COMPUTED-TOMOGRAPHY; EARLY PREDICTION; PHASE-II; EVALUATION CRITERIA; CHOI CRITERIA; FOLLOW-UP;
D O I
10.1007/s40336-017-0229-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Improvement of the therapeutic approaches in gastrointestinal stromal tumors (GIST) by the introduction of targeted therapies requires appropriate diagnostic tools, which allow sufficient assessment of therapeutic response, including differentiation of true progression from pseudoprogression due to myxoid degeneration or intratumoral hemorrhage. In this literature review the impact and limitations of different imaging modalities used in GIST therapy monitoring are discussed. Methods PubMed and Cochrane library search were performed using appropriate keywords. Overall, 39 original papers fulfilled the defined criteria and were included in this systematic review. Results Morphological imaging modalities like computed tomography (CT) are primarily used for both diagnosis and therapy monitoring. However, therapy with tyrosine kinase inhibitors and other targeted therapies in GIST may lead only to a minor tumor volume reduction even in cases of response. Therefore, the use of Response Evaluation Criteria in Solid Tumors (RECIST) has limitations. To overcome those limitations, modified response criteria have been introduced for the CT-based therapy assessment, like the Choi criteria as well as criteria based on dual energy CT studies. Functional imaging techniques, mostly based on FDG PET-CT are in use, in particular for the assessment of early treatment response. Conclusions The impact and the limitations of PET-based therapy monitoring, as well as its comparison with CT, MRI and survival data are discussed in this review. CT is still the standard method for the evaluation of therapy response despite its several limitations. FDG PET-CT is helpful for the assessment of early therapy response; however, more prospective data are needed to define its role as well as the appropriate time intervals for therapy monitoring. A multiparametric evaluation based on changes in both morphological and functional data has to be assessed in further prospective studies.
引用
收藏
页码:183 / 197
页数:15
相关论文
共 50 条
  • [1] Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review
    Antonia Dimitrakopoulou-Strauss
    Ulrich Ronellenfitsch
    Caixia Cheng
    Leyun Pan
    Christos Sachpekidis
    Peter Hohenberger
    Thomas Henzler
    Clinical and Translational Imaging, 2017, 5 : 183 - 197
  • [2] Correction to: Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review
    Antonia Dimitrakopoulou-Strauss
    Ulrich Ronellenfitsch
    Caixia Cheng
    Leyun Pan
    Christos Sachpekidis
    Peter Hohenberger
    Thomas Henzler
    Clinical and Translational Imaging, 2017, 5 : 575 - 575
  • [3] Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review (vol 5, pg 183, 2017)
    Dimitrakopoulou-Strauss, Antonia
    Ronellenfitsch, Ulrich
    Cheng, Caixia
    Pan, Leyun
    Sachpekidis, Christos
    Hohenberger, Peter
    Henzler, Thomas
    CLINICAL AND TRANSLATIONAL IMAGING, 2017, 5 (06) : 575 - 575
  • [4] Evaluation of 18F-FDG-PET/CT in comparison with conventional imaging in gastrointestinal stromal tumors (GIST).
    Vlachou, F.
    Efthimiadou, R.
    Gogou, L.
    Filipi, V.
    Nikaki, A.
    Archontaki, A.
    Dalianis, K.
    Gogos, K.
    Andreou, J.
    Prassopoulos, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S356 - S356
  • [5] Response to Imatinib mesylate (GleevecTM) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT
    Van den Abbeele, AD
    Badawi, RD
    Cliche, J
    Israel, DA
    Dimitrijevic, S
    Demetri, GD
    RADIOLOGY, 2002, 225 : 424 - 424
  • [6] A Single Institutional Retrospective Experience with Fdg Pet/Ct on Treatment Response and Follow-up of Gastrointestinal Stromal Tumors (Gist)
    Sen, F.
    Akpinar, A. T.
    Kumtepe, D.
    Ogur, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S387 - S388
  • [7] The contribution of PET/18FDG for the evaluation of therapy response in gastrointestinal stromal tumor (GIST)
    Makaiova, I
    Kovacova, S
    Vesely, J
    Koza, I
    Sufliarsky, J
    Studeny, M
    Salek, T
    Procka, V
    Banki, P
    Spanik, S
    Kausitz, J
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S335 - S335
  • [8] A gist of gastrointestinal stromal tumors: A review
    Rammohan, Ashwin
    Sathyanesan, Jeswanth
    Rajendran, Kamalakannan
    Pitchaimuthu, Anbalagan
    Perumal, Senthil-Kumar
    Srinivasan, U. P.
    Ramasamy, Ravi
    Palaniappan, Ravichandran
    Govindan, Manoharan
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 5 (06) : 102 - 112
  • [9] A gist of gastrointestinal stromal tumors: A review
    Ashwin Rammohan
    Jeswanth Sathyanesan
    Kamalakannan Rajendran
    Anbalagan Pitchaimuthu
    Senthil-Kumar Perumal
    UP Srinivasan
    Ravi Ramasamy
    Ravichandran Palaniappan
    Manoharan Govindan
    World Journal of Gastrointestinal Oncology, 2013, (06) : 102 - 112
  • [10] Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with Gastrointestinal Stromal Tumors (GIST)
    Simo, M
    Garcia, JR
    Soler, M
    Perez, G
    Lopez, S
    Lomena, F
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S335 - S335